Dilara Sonmez

Dilara Sonmez

Auto-generated profile, based on publicly available information

Dilara Sonmez

Istanbul Universitesi

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 March 2023 in Computer Methods and Programs in Biomedicine
Verified
Journal Article
Closed access
ZGZozan Guleken
Zozan Guleken
PJPaweł Jakubczyk
Paweł Jakubczyk
WPWieslaw Paja
Wieslaw Paja
KPKrzysztof Pancerz
Krzysztof Pancerz
AWAgnieszka Wosiak
Agnieszka Wosiak
JDJoanna Depciuch
Joanna Depciuch


8 December 2025 in Urologic Oncology: Seminars and Original Investigations
Verified
Journal Article
Closed access
KKKemal Kayar
Kemal Kayar
RKRıdvan Kayar
Rıdvan Kayar
DSDilara Sönmez
Dilara Sönmez
MHMehmet Tolgahan Hakan
Mehmet Tolgahan Hakan
CHCem Horozoğlu
Cem Horozoğlu
LVLevent Verim
Levent Verim

10 March 2023 in Biotechnology & Biotechnological Equipment
Verified
Journal Article
Open access
OBOsman Bilen
Osman Bilen
LVLevent Verim
Levent Verim
CTCagatay Tosun
Cagatay Tosun
OYOmer Yuksel
Omer Yuksel
USUlgen Sever
Ulgen Sever
IYIlhan Yaylim
Ilhan Yaylim

1 January 2021 in Annals of Medical Research
Verified
Journal Article
Open access
HOHamza Malik Okuyan
Hamza Malik Okuyan
AAAhmet Arslan
Ahmet Arslan
YIYusuf Igci
Yusuf Igci
BGBulent Gogebakan
Bulent Gogebakan
NBNilufer Bilgic
Nilufer Bilgic
DSDilara Sonmez
Dilara Sonmez

26 August 2026 in Scientific Reports
Verified
Journal Article
Open access
PDF file
MHMehmet Tolgahan Hakan
Mehmet Tolgahan Hakan
ŞDŞeyda Demirkol
Şeyda Demirkol
DZDilara Sönmez Zor
Dilara Sönmez Zor
CHCem Horozoğlu
Cem Horozoğlu
OKOzlem Kucukhuseyin
Ozlem Kucukhuseyin
IYIlhan Yaylim
Ilhan Yaylim
IDO1 contributes to tumor-associated immunosuppression by regulating tryptophan catabolism. This study investigated the immunometabolic tryptophan-kynurenine axis in NSCLC by evaluating circulating tryptophan metabolites, the IDO1 rs10089084 genetic variation, IDO1/PD-L1 expression in tumor tissues of NSCLC patients, and soluble sPD-1 in relation to clinicopathological features. Seventy NSCLC patients and 72 healthy controls were included in the study. Plasma TRP, KYN, and KYNA levels were analyzed by high-performance liquid chromatography, IDO1 rs10089084 gene variants by PCR–RFLP, IDO1/PD-L1 expression levels in tumor and adjacent non-tumor tissues by quantitative PCR, and sPD-1 levels by ELISA. Lower TRP levels, higher KYN levels, and increased KYN/TRP ratios were detected in individuals with the IDO1 CC genotype. Correlation analyses supported a possible association between systemic tryptophan-kynurenine metabolism and intratumoral IDO1/PD-L1-related immune-metabolic activity. ROC results demonstrated that decreased TRP and increased KYN/TRP values can differentiate NSCLC patients from healthy controls. Locally advanced disease was associated with lower TRP levels and increased KYN/TRP ratios compared to early-stage disease. Our findings suggest that integrated assessment of TRP-KYN pathway metabolites with IDO1 genetic variation and IDO1/PD-L1 expression may aid in characterizing immunometabolic alterations in NSCLC and support the development of biomarker-based approaches for disease stratification and progression assessment.